行情

NBRV

NBRV

Nabriva
NASDAQ

实时行情|Nasdaq Last Sale

1.770
-0.030
-1.67%
盘后: 1.800 +0.03 +1.69% 17:55 12/11 EST
开盘
1.780
昨收
1.800
最高
1.829
最低
1.760
成交量
75.63万
成交额
--
52周最高
3.270
52周最低
1.120
市值
1.39亿
市盈率(TTM)
-1.1597
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBRV 新闻

  • Investors Who Bought Nabriva Therapeutics (NASDAQ:NBRV) Shares A Year Ago Are Now Down 11%
  • Simply Wall St..1天前
  • 兴业银行:美国国债收益率或将因衰退风险而跌至1.2%
  • 新浪财经综合.12/03 05:39
  • 美股超级牛派:最近的下跌是早来的圣诞礼物
  • 新浪财经.12/03 05:36
  • 英工党领袖致信特朗普:不会卖出国家医疗服务系统
  • 中国新闻网.12/03 05:24

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

NBRV 简况

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
展开

Webull提供Nabriva Therapeutics PLC - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。